# Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

> **NCT01839968** · — · COMPLETED · sponsor: **University Hospital, Geneva** · enrollment: 32 (actual)

## Conditions studied

- Acquired Platelet Disorder

## Interventions

- **OTHER:** Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma

## Key facts

- **NCT ID:** NCT01839968
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01839968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01839968, "Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01839968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*